Stock Track | Moderna Soars 5.17% Intraday on Analyst Price Target Hikes
Stock Track
Jun 26
Moderna Inc. (MRNA) saw its stock price surge 5.17% during intraday trading on Friday, following a series of positive analyst actions.
The rally was driven by multiple investment firms raising their price targets for the biotechnology company. Piper Sandler increased its target price to $77 from $69, while Jefferies raised its target to $53 from $45, though maintaining a hold rating on the stock.
Analysts have been actively weighing in on Moderna and other healthcare stocks this week, with mixed opinions emerging about the sector's prospects. The upward revisions in price targets appear to have boosted investor confidence in the company's outlook.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.